touchPODCAST

Improving outcomes of immune-related adverse events: The crucial role of the pharmacist

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of three oncology pharmacists discuss how to improve outcomes for patients experiencing immune-related adverse events after receiving immunotherapy for cancer treatment. 

The experts; 

• Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA; 
• Dr Sonia Amin Thomas, Wellstar North Fulton Hospital and Northwest Georgia Oncology Center, Roswell, GA, USA; 
• Ms Meera Desai, University College London Hospitals NHS Foundation Trust, London, UK; 

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from MSD and is jointly provided by USF Health and touchIME. 

For further information visit: https://touchoncologyime.org/pharmacist-role-iraes/ 

Optimizing patient outcomes in Cushing’s disease

touchMDT for touchENDOCRINOLOGY

An endocrinologist, a pituitary surgeon, a pituitary nurse specialist and a patient with Cushing's disease in remission share their views on how the multidisciplinary team can support patients with Cushing’s disease.

The multidisciplinary team

• Pituitary surgeon: Dr Timothy Smith, Boston, MA, USA
• Endocrinologist: Dr Laurence Katznelson, Stanford, CA, USA
• Pituitary nurse specialist: Mrs Sandra Ramsburg, Baltimore, MD, USA
• Patient in remission/patient advocate: Ms Sharmyn McGraw, Orange County, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Recordati Rare Diseases and Xeris Pharmaceuticals, Inc., and is jointly provided by USF Health and touchIME.

For further information visit our website: touchENDOCRINOLOGY

 

Treatment pathways with a focus on medical therapies for Cushing’s disease

touchMDT for touchENDOCRINOLOGY

An endocrinologist, a pituitary surgeon and a pituitary nurse specialist review treatment pathways for patients with Cushing’s disease, with a focus on medical therapies, and provide insights on the efficacy and safety of approved medical agents.

• Pituitary surgeon: Dr Timothy Smith, Boston, MA, USA,
• Endocrinologist: Dr Laurence Katznelson, Stanford, CA, USA,
• Pituitary nurse specialist: Mrs Sandra Ramsburg, Baltimore, MD, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Recordati Rare Diseases and Xeris Pharmaceuticals, Inc., and is jointly provided by USF Health and touchIME.

For further information visit our website: 
touchENDOCRINOLOGY

Managing Cushing’s disease and goals of medical therapy

touchMDT for touchENDOCRINOLOGY

A pituitary surgeon, an endocrinologist and a patient with Cushing’s disease in remission discuss management challenges, including diagnostic delay and associated comorbidities, and the goals of medical therapy in Cushing’s disease.

The multidisciplinary team

• Pituitary surgeon: Dr Timothy Smith, Boston, MA, USA,
• Endocrinologist: Dr Laurence Katznelson, Stanford, CA, USA,
• Patient in remission/patient advocate: Ms Sharmyn McGraw, Orange County, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Recordati Rare Diseases and Xeris Pharmaceuticals, Inc., and is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchENDOCRINOLOGY

 

 

Optimizing strategies for the treatment of colorectal cancer in the biomarker era - Module 1

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of leading experts discuss the role of biomarkers in optimizing the treatment of colorectal cancer, and how biomarkers are shaping the evolving treatment landscape.

 The experts

• Dr Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan
• Dr Chiara Cremolini, University of Pisa, Pisa, Italy
• Dr Rachel Riechelmann, AC Camargo Cancer Center, São Paulo, Brazil

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information please visit: https://touchoncologyime.org/pd-treatment-of-crc-in-the-biomarker-era/ 

MDT perspectives on novel approaches to overcome resistance with standard-of-care immunotherapy for non-driver mutation metastatic NSCLC

touchMDT for touchONCOLOGY

Listen to key experts from a multidisciplinary team review novel approaches to overcome resistance to standard-of-care immunotherapy for non-driver mutation metastatic NSCLC, including new immune checkpoint inhibitor combinations and emerging novel targets.

The multidisciplinary team:

• Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA
• Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/

MDT perspectives on tracking prognostic and predictive biomarkers for immunotherapy

touchMDT for touchONCOLOGY

Listen to key experts from a multidisciplinary team discuss the tools used to predict response to immunotherapy, and they review emerging biomarkers.

The multidisciplinary team:

• Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany
• Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/ 

MDT and patient perspectives on shared decision making for emerging treatment options

touchMDT for touchONCOLOGY

Listen to key experts from a multidisciplinary team, plus a survivor of metastatic NSCLC, discuss the importance of involving patients in their treatment decisions and how clinicians can best support patients throughout their treatment journey.

The multidisciplinary team:

• Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK
• Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA
• Patient Advocate: Mr Josh Colow, Woodstock, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/

MDT perspectives on the limitations of standard of care immunotherapy for non-driver mutation metastatic NSCLC

touchMDT for touchONCOLOGY

Listen to key experts from a multidisciplinary team discuss the challenges associated with standard-of-care immunotherapy for metastatic NSCLC without driver mutations, including treatment resistance and toxicity.

The multidisciplinary team:

• Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK
• Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA
• Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/ 

Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?

touchPANEL DISCUSSION for touchHAEMATOLOGY

Listen to a panel of leading experts discuss the burden and clinical presentation of pyruvate kinase (PK) deficiency, the current treatment strategies and remaining unmet treatment need, and future approaches to managing the disease. 

The experts:

• Dr Rachael Grace, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA
• Dr Hanny Al-Samkari, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
• Prof. Ami J Shah, Lucile Packard Children’s Hospital Stanford, and Stanford University, Palo Alto, CA, USA

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Agios Pharmaceuticals. This activity is jointly provided by USF Health and touchIME. 

For further information please visit: https://touchhaematologyime.org/pd-navigating-pyruvate-kinase-deficiency-today/